Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL120845 | 1.00 | TSHR (0.35) | TSHRRECQLSPHK2SPHK1 | |
| Hydrochloric Acid SCHEMBL3613960 | 0.97 | SPHK2 (0.35) | TSHRRECQLSPHK2SPHK1 | |
| Hydrochloric Acid SCHEMBL164104 | 0.97 | SPHK2 (0.35) | TSHRRECQLSPHK2SPHK1 | |
| Hydrochloric Acid SCHEMBL351073 | 0.97 | SPHK2 (0.35) | TSHRRECQLSPHK2SPHK1 | |
| Hydrochloric Acid SCHEMBL988664 | 0.97 | SPHK2 (0.35) | TSHRRECQLSPHK2SPHK1 | |
| SCHEMBL44180 | 0.97 | TSHR (0.36) | TSHRRECQLSPHK2SPHK1 | |
| SCHEMBL44286 | 0.94 | SPHK2 (0.36) | TSHRRECQLSPHK2SPHK1 | |
| SCHEMBL43895 | 0.94 | SPHK2 (0.36) | TSHRRECQLSPHK2SPHK1 | |
| Hydrochloric Acid SCHEMBL29067643 | 0.88 | SPHK2 (0.33) | TSHRRECQLSPHK2SPHK1 | |
| Hydrochloric Acid SCHEMBL9257403 | 0.87 | TSHR (0.33) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 669 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4699621-A2 | SPECIFIC MODIFICATION OF ANTIBODY WITH IGG-BINDING PEPTIDE | Kagoshima University (JP) | 2026-02-25 | — | — | EP | claimed |
| US-20260021213-A1 | METHOD FOR PRODUCING FC-CONTAINING MOLECULE MODIFYING REAGENT | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2026-01-22 | — | — | US | claimed |
| EP-3299383-B1 | SPECIFIC MODIFICATION OF ANTIBODY WITH IGG-BINDING PEPTIDE | UNIV KAGOSHIMA (JP) | 2025-12-03 | — | — | EP | claimed |
| US-RE50282-E1 | Specific modification of antibody with IgG-binding peptide | KAGOSHIMA UNIVERSITY (JP) | 2025-01-28 | — | — | US | claimed |
| EP-4491628-A1 | METHOD FOR PRODUCING FC-CONTAINING MOLECULE MODIFYING REAGENT | Nihon Medi-Physics Co., Ltd. (JP) | 2025-01-15 | — | — | EP | claimed |
| US-20240391950-A1 | PEPTIDE CROSSLINKING AGENT AND CROSSLINKED PEPTIDE WHICH IS CROSSLINKED USING SAID CROSSLINKING AGENT | KAGOSHIMA UNIVERSITY (JP) | 2024-11-28 | — | — | US | claimed |
| CN-118922433-A | Method for producing Fc molecule-containing modifying agent | 日本医事物理股份有限公司 | 2024-11-08 | — | — | CN | claimed |
| US-20240368223-A1 | SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE | KAGOSHIMA UNIVERSITY (JP) | 2024-11-07 | — | — | US | claimed |
| EP-3470418-B1 | SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IGG-BINDING PEPTIDE | UNIV KAGOSHIMA (JP) | 2024-07-31 | — | — | EP | claimed |
| WO-2023171809-A1 | METHOD FOR PRODUCING FC-CONTAINING MOLECULE MODIFYING REAGENT | 日本メジフィジックス株式会社 | 2023-09-14 | — | — | WO | claimed |
| EP-3299383-A1 | SPECIFIC MODIFICATION OF ANTIBODY WITH IgG-BINDING PEPTIDE | Kagoshima University (JP) | 2018-03-28 | — | — | EP | claimed |
| EP-0701448-B1 | AMPLIFICATION OF THE VITAMIN B 12 UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY LTD (AU) | 2002-08-14 | — | — | EP | claimed |
| EP-0701448-A4 | AMPLIFICATION OF THE VITAMIN B 12? UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY LTD (AU) | 1997-01-02 | — | — | EP | claimed |
| EP-0701448-A1 | AMPLIFICATION OF THE VITAMIN B 12? UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1996-03-20 | — | — | EP | claimed |
| US-5449720-A | Amplification of the VB12 uptake system using polymers | BIOTECH AUSTRALIA PTY LIMITED (AU) | 1995-09-12 | — | — | US | claimed |
| WO-1994027641-A1 | AMPLIFICATION OF THE VITAMIN B12 UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1994-12-08 | — | — | WO | claimed |
| EP-0248621-B1 | REAGENT FOR IMMUNOASSAY | KABUSHIKI KAISHA TOSHIBA (JP) | 1992-08-26 | — | — | EP | claimed |
| US-5053388-A | Coating corneal incision with protein crosslinking compound, applying extra cellular matrix material, both with carriers | CHIRON OPHTHALMICS, INC. (US) | 1991-10-01 | — | — | US | claimed |
| WO-1989004172-A1 | WOUND HEALING COMPOSITION AND METHOD | CHIRON OPHTHALMICS INC. (US) | 1989-05-18 | — | — | WO | claimed |
| US-4245005-A | CHROMATOGRAPHY, CROSSLINKED COATING | PURDUE RESEARCH FOUNDATION (US) | 1981-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391950-A1 | PEPTIDE CROSSLINKING AGENT AND CROSSLINKED PEPTIDE WHICH IS CROSSLINKED USING SAID CROSSLINKING AGENT | PTMA, PTMS, CDC37 | TSHR 1619/4885RECQL 2457/4885SPHK2 4256/4885 |
| US-20260021213-A1 | METHOD FOR PRODUCING FC-CONTAINING MOLECULE MODIFYING REAGENT | PTMS, FCGR1A, F13B | TSHR 865/4885RECQL 3668/4885SPHK2 2539/4885 |
| US-20240368223-A1 | SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE | FCGR3B, NGLY1, FCGR2A | TSHR 375/4885RECQL 4307/4885SPHK2 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.